- Home
- TOPS vs NRXS Comparison
TOPS vs NRXS Comparison
Compare TOPS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- NRXS
- Stock Information
- Founded
- TOPS 2000
- NRXS 2011
- Country
- TOPS Greece
- NRXS United States
- Employees
- TOPS N/A
- NRXS N/A
- Industry
- TOPS Marine Transportation
- NRXS
- Sector
- TOPS Consumer Discretionary
- NRXS
- Exchange
- TOPS Nasdaq
- NRXS Nasdaq
- Market Cap
- TOPS 27.2M
- NRXS 25.0M
- IPO Year
- TOPS 2004
- NRXS 2023
- Fundamental
- Price
- TOPS $5.46
- NRXS $2.46
- Analyst Decision
- TOPS
- NRXS Strong Buy
- Analyst Count
- TOPS 0
- NRXS 1
- Target Price
- TOPS N/A
- NRXS $7.00
- AVG Volume (30 Days)
- TOPS 8.3K
- NRXS 54.3K
- Earning Date
- TOPS 11-13-2025
- NRXS 08-12-2025
- Dividend Yield
- TOPS N/A
- NRXS N/A
- EPS Growth
- TOPS N/A
- NRXS N/A
- EPS
- TOPS 1.09
- NRXS N/A
- Revenue
- TOPS $86,127,000.00
- NRXS $3,217,531.00
- Revenue This Year
- TOPS $9.90
- NRXS $62.14
- Revenue Next Year
- TOPS N/A
- NRXS $131.87
- P/E Ratio
- TOPS $4.99
- NRXS N/A
- Revenue Growth
- TOPS 3.83
- NRXS 41.93
- 52 Week Low
- TOPS $5.00
- NRXS $1.33
- 52 Week High
- TOPS $11.47
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- TOPS 40.92
- NRXS 48.19
- Support Level
- TOPS $5.40
- NRXS $2.35
- Resistance Level
- TOPS $5.70
- NRXS $2.68
- Average True Range (ATR)
- TOPS 0.23
- NRXS 0.13
- MACD
- TOPS -0.01
- NRXS 0.02
- Stochastic Oscillator
- TOPS 13.00
- NRXS 49.07
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).